Table of Contents
ISRN Rheumatology
Volume 2014, Article ID 852954, 7 pages
Review Article

Review of Hyperuricemia as New Marker for Metabolic Syndrome

Department of Medicine, The George Washington University, 2150 Pennsylvania Avenue, NW, Washington, DC 20037, USA

Received 5 August 2013; Accepted 12 December 2013; Published 16 February 2014

Academic Editors: C. V. Albanese, C.-J. Chen, and E. Tchetina

Copyright © 2014 Laura Billiet et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Hyperuricemia has long been established as the major etiologic factor in gout. In recent years, a large body of evidence has accumulated that suggests that hyperuricemia may play a role in the development and pathogenesis of a number of metabolic, hemodynamic, and systemic pathologic diseases, including metabolic syndrome, hypertension, stroke, and atherosclerosis. A number of epidemiologic studies have linked hyperuricemia with each of these disorders. In some studies, therapies that lower uric acid may prevent or improve certain components of the metabolic syndrome. There is an association between uric acid and the development of systemic lupus erythematosus; the connection between other rheumatic diseases such as rheumatoid arthritis and osteoarthritis is less clear. The mechanism for the role of uric acid in disorders other than gout is not well established but recent investigations point towards systemic inflammation induced by urate, as the major pathophysiological event common to systemic diseases, including atherosclerosis.